Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAT 1308

X
Drug Profile

BAT 1308

Alternative Names: BAT-1308; Recombinant humanized anti PD-1 monoclonal antibody injection

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bio-Thera Solutions
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Solid tumours
  • Phase II/III Endometrial cancer

Most Recent Events

  • 02 Apr 2024 Bio-Thera Solutions plans a phase I/II trial for Solid tumours (Late stage disease, Metastatic disease, Combination therapy) (IV, Injection) (NCT06341114)
  • 20 Mar 2024 Phase-II/III clinical trials in Endometrial cancer (Combination therapy, First-line therapy, Late-stage disease, Recurrent) in China (IV) (NCT06321068)
  • 06 Mar 2024 Bio-Thera Solutions initiates a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in China (IV) (NCT06139536)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top